UPDATE 2-European shares rise on China trade data, easing coronavirus worries

* STOXX 600 hovers near one-month high
* Spanish shares rise as some businesses re-open
* London-listed stocks lag broader rally
* AstraZeneca jumps on coronavirus clinical trial update

(Adds comments, updates to close)
By Shreyashi Sanyal and Sagarika Jaisinghani
April 14 (Reuters) - European shares ended higher on
Tuesday, as better-than-expected data from China added to signs
that sweeping lockdowns to contain the spread of the coronavirus
were working.
The pan-European STOXX 600 index .STOXX closed up 0.6%
after a strong finish last week that was powered by another
aggressive round of stimulus and tentative signs of the virus
peaking in some hot spots.
"There are hopes that the COVID-19 pandemic is reaching an
inflection point and that the EU will muddle its way through,"
said Cameron Brandt, director of research at fund flow data
provider EPFR.
"Cheaper energy, inventory restocking and pent-up demand
will fuel a significant rebound in economic activity during the
second half of 2020."
Spanish shares .IBEX gained 0.5% as some businesses
re-opened on Monday, although shops, bars and public spaces were
set to stay closed until at least April 26.
Almost all the major European country bourses were trading
higher, with sentiment also lifted by data showing a
smaller-than-expected decline in China's exports and imports.
Analysts, however, warned a sure-footed recovery was months
away.
The benchmark STOXX 600 index .STOXX has recovered about
24% - or nearly $2 trillion in market value - in the past month,
fuelled by a raft of global fiscal and monetary stimulus,
including the half-a-trillion euros worth of support for
European economies announced last week. Although the index remains 22.5% below its mid-February
record highs, Europe's volatility gauge .V2TX has steadily
declined since hitting a record high mid-March and is now at
levels last seen in 2015.
The focus this week will also be on U.S. corporate earnings
for a first glimpse of the business havoc wreaked by the health
crisis. In Europe, earnings for STOXX 600 firms are expected to
decline 22% in the first quarter and 34.2% in the second.
"Even though there will be a recession in earnings and they
might fall even more than during the financial crisis, they will
also bounce back much quicker," said Simona Gambarini, markets
economist at Capital Economics.
"So investors might look through a period of weakness
because ultimately, it doesn't quite matter as much if the
weakness is only temporary."
Health care stocks .SXDP were among top gainers across
European subsectors, with AstraZeneca AZN.L surging 6.8% after
saying it would start a clinical trial to assess the potential
of Calquence in the treatment of severe COVID-19 patients.
Swedish rare disease drugmaker Sobi SOBIV.ST jumped 6.3%
to the top of the STOXX 600 after reporting
stronger-than-expected first-quarter earnings as the pandemic
spurred higher demand for some of its pharmaceuticals.
London's FTSE 100 .FTSE lagged the broader rally, weighed
down by oil stocks and a slump in British American Tobacco
BAT.L on reports of a U.S. criminal probe and on signs Britain
will remain under lockdown for a longer period. .L